Physician profile
Tarun Rai
NPI 1821304353
$2,952.12
in general payments reported to CMS, 2019-2025
25 companies · $675 in 2025
The $675 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $31.21 · 2021: $314 · 2022: $237 · 2023: $786 · 2024: $630 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,532.39 | 2019-2025 | |
| Pfizer INC. | $179.58 | 2023-2025 | |
| Madrigal Pharmaceuticals | $146.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $143.33 | 2021-2025 | Stelara, Tremfya |
| Celgene Corporation | $123.83 | 2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.51 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $112.25 | 2022-2025 | |
| Boston Scientific Corporation | $86.39 | 2021 | |
| Qol Medical, LLC | $68.13 | 2024-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $62.94 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $56.31 | 2019-2025 | Eohilia, Entyvio |
| Genzyme Corporation | $45.43 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $43.56 | 2023-2024 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $32.37 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $30.57 | 2020-2023 | Ocaliva |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $22.03 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $22.01 | 2019 | |
| Ucb, INC. | $19.78 | 2019 | |
| Vivus LLC | $18.17 | 2023 | Qsymia |
| Lilly USA, LLC | $16.25 | 2024 | Omvoh |
| Concordia Pharmaceuticals INC. | $15.37 | 2019 | |
| Amgen INC. | $14.28 | 2025 | Uplizna |
| Ferring Pharmaceuticals INC. | $13.85 | 2022 | |
| Aimmune Therapeutics, INC. | $13.68 | 2024 | |
| Shionogi INC | $12.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tarun Rai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.